Teleflex (NYSE:TFX – Get Free Report) had its price objective boosted by analysts at Truist Financial from $142.00 to $167.00 in a research report issued on Monday, Benzinga reports. The brokerage currently has a “hold” rating on the medical technology company’s stock. Truist Financial‘s price target points to a potential upside of 11.04% from the stock’s previous close.
Several other analysts have also commented on the stock. Needham & Company LLC lifted their price objective on shares of Teleflex from $159.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, August 25th. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research note on Monday, September 21st. Bank of America raised shares of Teleflex from a “neutral” rating to a “buy” rating and increased their target price for the company from $145.00 to $158.00 in a research report on Monday, September 28th. Mizuho set a $160.00 price target on shares of Teleflex in a research note on Friday. Finally, Wells Fargo & Company lifted their price target on shares of Teleflex from $138.00 to $167.00 and gave the stock an “equal weight” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $163.30.
Get Our Latest Stock Report on TFX
Teleflex Trading Down 0.3%
Shares of Teleflex stock opened at $150.39 on Monday. Teleflex has a 1 year low of $100.18 and a 1 year high of $156.67. The firm has a market cap of $6.37 billion, a PE ratio of 18.30, a P/E/G ratio of 0.96 and a beta of 0.85. The stock has a fifty day moving average price of $132.15 and a 200-day moving average price of $126.09. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.01 and a quick ratio of 1.59.
Teleflex (NYSE:TFX – Get Free Report) last released its earnings results on Thursday, November 5th. The medical technology company reported $2.63 EPS for the quarter, topping analysts’ consensus estimates of $1.90 by $0.73. The company had revenue of $567.80 million for the quarter, compared to analysts’ expectations of $565.52 million. Teleflex had a return on equity of 10.57% and a net margin of 13.51%. The business’s revenue for the quarter was up .1% compared to the same quarter last year. During the same period in the previous year, the business posted $3.67 EPS. Equities research analysts anticipate that Teleflex will post 7.63 EPS for the current year.
Institutional Investors Weigh In On Teleflex
Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Teleflex during the second quarter valued at about $688,537,000. Jupiter Topco LLC bought a new position in Teleflex during the second quarter worth about $550,456,000. Janus Henderson Group PLC boosted its position in Teleflex by 1.1% during the first quarter. Janus Henderson Group PLC now owns 4,291,311 shares of the medical technology company’s stock worth $513,281,000 after purchasing an additional 45,199 shares during the period. Irenic Capital Management LP bought a new position in Teleflex during the first quarter worth about $104,061,000. Finally, Pzena Investment Management LLC purchased a new position in shares of Teleflex in the second quarter worth about $76,462,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.
Teleflex Company Profile
Teleflex is a global medical technology company that develops, manufactures and markets single-use medical devices used by healthcare professionals in hospitals and other care settings. Its products support a range of procedures, including vascular access, anesthesia, critical care, surgery, urology and emergency medicine.
The company’s offerings include vascular and interventional access devices, catheters, airway management products, surgical instruments and other devices used in diagnostic and therapeutic procedures.
Further Reading
- Five stocks we like better than Teleflex
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.
